HIFU Overview
Focal One HIFU uses ultrasound technology to precisely target prostate tissue.
focalone.comCrawled Nov 10, 2026
Focal One HIFU uses ultrasound technology to precisely target prostate tissue.
The page explains how Focal One combines imaging and HIFU technology.
Focal One’s focal therapy and HIFU technology support prostate cancer management with precise treatment options.
The page describes robotic-assisted focal HIFU technology for millimeter-precise prostate treatment while sparing surrounding tissue.
Focal One offers a non-invasive prostate treatment using high intensity focused ultrasound (HIFU), while sparing healthy surrounding tissue.
Find HIFU in the news spotlighting stories and posts featuring HIFU prostate treatment options programs across the United States.
FocalTherics designs robotic medical devices for diagnosing and treating prostate cancer. Its Focal One Robotic HIFU System offers image-guided, minimally invasive treatment.
FocalTherics develops robotic medical devices for prostate cancer diagnosis and treatment. Its Focal One Robotic HIFU System provides image-guided, minimally invasive solutions.
The Focal One robotic HIFU system uses HIFU technology to target and destroy part of the prostate while sparing healthy tissue, minimizing side effects for prostate cancer patients.
Focal One’s management team has experience in medical device market development. The company uses HIFU technology to precisely target and destroy part of the prostate while sparing surrounding tissue.
EDAP TMS develops, produces, and distributes minimally invasive medical devices for urology using proprietary ultrasound technology. The company operates a global network of subsidiaries and distributors.
Focal One offers a non-invasive prostate treatment using high intensity focused ultrasound (HIFU), while sparing healthy surrounding tissue and minimizing side effects.
The page describes robotic-assisted focal therapy for prostate cancer, offering precise treatment without surgery, radiation, or implants.
FocalTherics (formerly EDAP TMS S.A.) rebrands to emphasize its focus on robotic focal therapy. The company introduces a new trading symbol, **FOCL**, effective June 1, 2026. The shift aligns with its specialization in minimally invasive medical treatments.
FocalTherics™ rebrands from EDAP to emphasize its specialization in robotic focal therapy solutions. The company develops advanced medical technologies for targeted treatment applications. This shift aligns with its exclusive focus on high-growth robotic therapy innovations.
EDAP TMS and Telix Pharmaceuticals are collaborating to combine EDAP’s **Focal One Robotic HIFU** system with Telix’s **PSMA PET imaging** for prostate cancer treatment. The partnership aims to advance **joint clinical research** and **physician education** on integrating these technologies. The focus is on improving precision in prostate cancer management through theranostics—therapeutic and diagnostic approaches.
EDAP TMS SA, a leader in robotic energy-based therapies, announces an Investor Day event for analysts and investors on June 1, 2026. The company will present its strategy and updates during the session scheduled for 8:00 am ET. This marks a key engagement opportunity for stakeholders to learn about its latest developments in medical robotics.
The **University of Washington Medicine** is deploying **EDAP TMS’s Focal One® robotic HIFU system** to perform targeted prostate tissue ablation. The program launches at **UW Medical Center**, marking the first implementation of this high-intensity focused ultrasound technology in the region. The system enables minimally invasive treatment for prostate conditions.